Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study

被引：0
|
作者：
Strand, Vibeke [1 ]
Tundia, Namita [2 ]
Friedman, Alan [2 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] AbbVie Inc, N Chicago, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
501
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Long-term quality-of-life and patient-reported improve-ments with garadacimab for hereditary angioedema: Phase 3 open-label extension study
    Aygoeren-Puersuen, E.
    Chapdelain, H.
    Sitz, K.
    Katelaris, C. H.
    Staubach, P.
    Magerl, M.
    Saguer, I. Martinez
    Guilarte, M.
    Longhurst, H.
    Lawo, J. -P
    Braverman, J.
    Lumry, W. R.
    ALLERGOLOGIE, 2024, 47 (09)
  • [32] LONG-TERM TOLERABILITY OF ZONISAMIDE IN PAEDIATRIC PATIENTS WITH EPILEPSY: RESULTS OF A PHASE II, OPEN-LABEL, EXTENSION STUDY
    Chouette, I.
    Giorgi, L.
    EPILEPSIA, 2012, 53 : 53 - 53
  • [33] Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
    Santos, Raul D.
    Duell, P. Barton
    East, Cara
    Guyton, John R.
    Moriarty, Patrick M.
    Chin, Wai
    Mittleman, Robert S.
    EUROPEAN HEART JOURNAL, 2015, 36 (09) : 566 - 575
  • [34] Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
    Winthrop, Kevin
    Vargas, Juan Ignacio
    Drescher, Edit
    Garcia, Conrado
    Friedman, Alan
    Hendrickson, Barbara
    Li, Yihan
    Klaff, Justin
    Kivitz, Alan
    RMD OPEN, 2022, 8 (01):
  • [35] LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS - RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4
    Feist, E.
    Nasonov, E.
    Luggen, M.
    Fatenejad, S.
    Grishin, S.
    Samsonov, M.
    Fleischmann, R. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 593 - 593
  • [36] Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis.
    Keystone, Edward C.
    Taylor, Peter C.
    Genovese, Mark C.
    Schlichting, Douglas E.
    De La Torre, Inmaculada
    Beattie, Scott D.
    Rooney, Terence
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1232 - S1232
  • [37] Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies
    Kelleher, Con J.
    Dmochowski, Roger R.
    Berriman, Sandra
    Kopp, Zoe S.
    Carlsson, Martin
    BJU INTERNATIONAL, 2012, 110 (03) : 392 - 400
  • [38] A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis).
    Wajdula, J
    Pedersen, R
    Sanda, M
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S229 - S229
  • [39] A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis).
    Willis, RF
    Pedersen, R
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 101 - 101
  • [40] Long-term efficacy and safety with zonisamide: Interim analysis of an open-label study
    Wroe, S
    Brodie, MJ
    EPILEPSIA, 2005, 46 : 118 - 118
12345